Skip Navigation LinksHome»Products»Product Details
Product In-Details

Broncho-Vaxom ® Adult Capsules

Broncho-Vaxom is an Immunostimulant for prevention and prophylaxis of upper and lower respiratory tract infections available as Capsules.

Ingredient: Lyophilized bacterial lysates
Multinational Partner: OM Pharma
Launch Date: January 1, 1989
Pack: Box of 1 strip each of 10 capsules

Product General

Disease Area

Acute bronchitis:

  • Acute bronchitis is an inflammation of the large bronchi in the lungs that is usually caused by viruses or bacteria and may last several days or weeks.
  • Characteristic symptoms include cough, sputum (phlegm) production, and shortness of breath and wheezing related to the obstruction of the inflamed airways.
  • Diagnosis is by clinical examination and sometimes microbiological examination of the phlegm.
  • Dry & painful cough (3-4 days) followed by mucopurulent cough.

Causes:

Contagious pathogens can cause acute bronchitis. In about half of instances of acute bronchitis, a bacterial or viral pathogen is identified. Typical viruses include respiratory syncytial virus, rhinovirus, influenza, and others; typical bacteria include Mycoplasma pneumonia, Chlamydophila pneumonia, Bordetella pertussis, streptococcus pneumonia, and haemophilus influenza.

Asthma:

  • Dyspnoeic crisis predominantly expiratory with sibilant ronchus
  • Asthma is the common chronic inflammatory disease of the airways characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm. Symptoms include wheezing, coughing, chest tightness, and shortness of breath.
  • Asthma is clinically classified according to the frequency of symptoms, forced expiratory volume in 1 second (FEV1), and peak expiratory flow rate.
  • Asthma may also be classified as atopic (extrinsic) or non-atopic (intrinsic).

COPD:

  • Disease state characterised by airflow limitation that is not fully reversible
  • Airflow obstruction associated with Chronic Bronchitis and Emphysema

Chronic bronchitis:

  • Bronchi inflammation & irritation causing chronic cough with morning predominant expectoration
  • During 3 consecutive months.
  • At least for 2 years .
  • No effort dyspnoea.

Emphysema:

  • Abnormal permanent enlargement of the distal airspaces, distal to the terminal bronchioles.
  • Accompanied by destruction of their walls and without obvious fibrosis.
Insert leaflet

Qualitative and quantitative composition:

1 capsule for adults contains: Lyophilized bacterial lysates of Haemophilus influenzae, Diplococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis: 7 mg.

1 capsule for children contains: Lyophilized bacterial lysates of Haemophilus influenzae, Diplococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis: 3,5 mg.

Therapeutic indications:

Prevention of recurrent infections of the airways and acute infectious exacerbations of chronic bronchitis. Comedication in the treatment of acute airway infections.

Posology and method of administration:

Oral route.

Adults:

Preventive treatment and/or consolidation therapy: 1 capsule daily on an empty stomach during 10 consecutive days per month for 3 months. Treatment of acute episodes: 1 capsule daily on an empty stomach until disappearance of the symptoms (but for at least 10 days). In cases in which antibiotics are needed, the administration of Broncho-Vaxom should be associated preferably from the start of therapy.

Children:

The capsule can be opened and the content poured into a drink (water, fruit juice, milk, etc.). Preventive treatment and/or consolidation therapy: 1 capsule daily on an empty stomach during 10 consecutive days per month for 3 months. Treatment of acute episodes: 1 capsule daily on an empty stomach until disappearance of the symptoms (but for at least 10 days). In cases in which antibiotics are needed, the administration of Broncho-Vaxom should be associated preferably from the start of therapy.

Publications

1-Documents Section

BV in mild to moderate COPD, 2007


BV in Chronic Bronchitis, 2005


BV in flu, 2005


BV in COPD, 2004


BV in COPD, 2004


BV is a cost effective in Adult , 2001


BV in sever COPD, 1997


BV in Asthma, 1997


BV is a cost effective, 1996


BV with Flu Vaccine, 1994


BV & Asthma, 1993


BV in COPD patients, 1993


BV in Chronic Bronchitis, 1989


BV in Sinusitis, 1989


BV in Recurrent Respiratory Tract Infections, 1983


BV in Chronic Bronchitis, 1981


BV in Post operative Respiratory Infections, 1980

Guidelines
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE

Attached Files

GOLD Updated 2013.pdf
GOLD 2011.pdf
GOLD 2009.pdf
GOLD 2008.pdf
Q & A
Does Broncho-Vaxom® interact with corticosteroids or antihistamines?

No

Immunodepressed patients: Can Broncho-Vaxom® be given to AIDS patients?

No

Auto-immune diseases: Can Broncho-Vaxom® be given to such patients

No And hepatitis is a contraindication

Time of dose: When should Broncho-Vaxom® be taken?

Ideally, in the morning on an empty stomach.

Anti-viral action: Does Broncho-Vaxom® have an anti-viral action?

Yes , it does indirectly, because it stimulates cell-mediated immunity.

Mechanism: How can oral Broncho-Vaxom® have an effect on the general immune response?

Because its absorption through the Peyer’s patches activates the mucosal response and then the general immune response.

Vaccination interaction: Can Broncho-Vaxom® be given during vaccination?

No. Although there is no interaction, there should be an interval of 1 week between them

Non-specific or specific: Which action does Broncho-Vaxom® have?

Because it stimulates macrophage activity = non-specific. It may also have some specific effect against the micro-organisms in its composition

Period of effective protection: After taking Broncho-Vaxom® over a 3-month period, how long can protection be expected to last?

Generally speaking, a 3-month course offer 6 months protection. For this reason, many doctors prescribe two courses of Broncho-Vaxom® per annum for their severe bronchitic patients, thus providing the needed protection for a 12-month period

Children: In view of the fact that the child’s immune system requires time to mature, from what age should Broncho-Vaxom® be given?

The newborn benefits from inherited maternal antibody protection. This has weakened by the age of about 6 months but by now the child’s own immune defences are maturing. So Broncho-Vaxom® can be given from 6 months of age

Cost: If a patient is already (and necessarily) taking antibiotics for a serious acute infection, isn’t a prescription for Broncho-Vaxom® simply adding to the costs of treatment?

These have solved the immediate problem but have not prevented infection recurrence. Broncho-Vaxom® will reduce the recurrence rate and so, over time, that patient will have fewer infections thus eliminating the need for antibiotics and hence reducing the costs of treatment.

There is no syrup form

The formulation is unstable in liquid form. None of the competitors have this formulation either

The dose seems to be complicated.

30 days (10+10+10) administration over a 3-month period provides 6 months coverage

At what time of the day is it best to take the Broncho-Vaxom capsules?

The capsule should be taken in the morning on an empty stomach; it is the best moment for an optimal effect of the product.

Scientific News

READ MORE »

Latest Products

Minapharm
Gonapure

Gonapure is a recombinant human follicle stimulating hormone of DNA origin; A high-tech outcome of a reliable technology.

Read MORE »

Newsletter Sign-up

Stay connected, subscribe to our newsletter for news and updates.

     

Office Address

Address: El-Bardissi St., 2T Takseem Asmaa Fahmy St., Heliopolis, Cairo - Egypt.
Phone: (+202) 2414-3170/1/2/3/4/5
Fax: (+202) 2414-3179

Social Media